Keywords: AstraZeneca, CEO and chairman resign, First-quarter 2012 financial results, The Medicines Company, Ischemic heart disease compound
AstraZeneca CEO to go early, as 1st-qtr sales and profits plunge; makes deal with TMC for cardiovasculars
Article | 26 April 2012
Anglo-Swedish drug major AstraZeneca (LSE: AZN) stunned the markets this morning, announcing that its chief executive David Brennan has decided ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- SciClone gains China rights to Zensun's Neucardin
